Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VELCADE Alone Or VELCADE Plus Docetaxel In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
NCT00064012Phase 2Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- May 2003
- Primary completion
- Jul 2004
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in non-small cell lung cancer (NSCLC), sponsored by University of Wisconsin–Madison. Started May 2003; status: completed.
02
Drugs
bortezomib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00064012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00064012.